Synlogic Inc. (SYBX) and Ra Pharmaceuticals Inc. (NASDAQ:RARX) Contrasting side by side

Synlogic Inc. (NASDAQ:SYBX) and Ra Pharmaceuticals Inc. (NASDAQ:RARX) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Synlogic Inc. 2 0.00 16.49M -2.00 0.00
Ra Pharmaceuticals Inc. 47 0.00 35.72M -1.92 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Synlogic Inc. and Ra Pharmaceuticals Inc.


Table 2 represents Synlogic Inc. (NASDAQ:SYBX) and Ra Pharmaceuticals Inc. (NASDAQ:RARX)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Synlogic Inc. 752,830,533.24% -38.9% -33.6%
Ra Pharmaceuticals Inc. 76,471,847.57% -47% -43.5%


The Current Ratio and a Quick Ratio of Synlogic Inc. are 11.5 and 11.5. Competitively, Ra Pharmaceuticals Inc. has 20.1 and 20.1 for Current and Quick Ratio. Ra Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Synlogic Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Synlogic Inc. and Ra Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Synlogic Inc. 1 0 0 1.00
Ra Pharmaceuticals Inc. 0 2 0 2.00

Synlogic Inc. has an average target price of $2, and a -9.71% downside potential. Meanwhile, Ra Pharmaceuticals Inc.’s average target price is $48, while its potential upside is 2.43%. The data provided earlier shows that Ra Pharmaceuticals Inc. appears more favorable than Synlogic Inc., based on analyst belief.

Institutional and Insider Ownership

Institutional investors held 82.8% of Synlogic Inc. shares and 99.9% of Ra Pharmaceuticals Inc. shares. About 25.2% of Synlogic Inc.’s share are held by insiders. Competitively, Ra Pharmaceuticals Inc. has 0.6% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Synlogic Inc. -9.95% -40.13% -35.81% -25.4% -39.74% -19.97%
Ra Pharmaceuticals Inc. -0.76% 2.81% 56.87% 72.27% 210.02% 87.03%

For the past year Synlogic Inc. has -19.97% weaker performance while Ra Pharmaceuticals Inc. has 87.03% stronger performance.


Ra Pharmaceuticals Inc. beats Synlogic Inc. on 7 of the 11 factors.

Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The companyÂ’s preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.